Catapult Therapeutics is focused on developing CAP-100, an innovative anti-CCR7 antibody designed to target hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHL). The unique mechanism of action of CAP-100 involves disrupting the migration and survival of tumor cells in lymph nodes, which is critical for the progression of these cancers. Preclinical studies have shown that CAP-100 effectively inhibits CCR7-induced tumor cell migration and promotes tumor cell killing through immune-mediated mechanisms, while sparing normal blood cells. This positions CAP-100 as a promising therapeutic option that can be used alone or in combination with existing treatments for hematological cancers.

The development of CAP-100 is underpinned by significant scientific discoveries, particularly those made by Dr. Cecilia Munoz and her team, who identified CCR7 as a key therapeutic target. The technology utilized to generate CAP-100 was developed by Pepscan, a Dutch biotech company, which enabled the creation of potent anti-CCR7 antibodies. Catapult Therapeutics is currently conducting a Phase I clinical trial to evaluate the safety and efficacy of CAP-100 in patients with relapsed or refractory CLL, with plans for further expansion in Europe. The company’s approach highlights the potential of targeting chemokine receptors, which have historically been challenging, to develop effective cancer therapies.

Netherlands

Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody.

Catapult Therapeutics

Company Details